The Liver Failure and Liver Regeneration Research Team is dedicated to in-depth exploration of the core pathological    molecular mechanisms underlying liver injury and regeneration, with the ultimate goal of overcoming critical    bottlenecks in clinical diagnosis and treatment. Concurrently, the team actively promotes the translation of    research findings and has established a rapid detection technology platform for infectious disease pathogens based    on CRISPR technology. Through multidisciplinary integration and technological convergence, we aim to provide    diagnostic and therapeutic solutions for public health.

Research Directions:

1. Basic and clinical research on liver failure injury and liver regeneration.

2. Development of rapid detection technologies for infectious disease pathogens based on CRISPR technology.

Our research interests are primarily focused on the following two areas: elucidating the key molecular mechanisms    involved in liver failure and liver regeneration, and searching for innovative regulatory targets for liver injury    and regeneration; and constructing a detection technology platform for emerging infectious disease pathogens.

Major Research Achievements:

1. Utilizing proteomics approaches, we identified the critical role of glycogen synthase kinase 3 beta (GSK3β) in    the pathogenesis of liver failure, clarifying its influence on the progression of acute liver failure through the    regulation of inflammatory responses, thereby providing a new therapeutic target for liver failure.

2. Systematically elucidated the specific molecular mechanisms of autophagy, endoplasmic reticulum stress, and PPARα    in liver failure, defining their potential value as biomarkers for disease warning and prognosis assessment.

3. Established novel rapid detection methods with high sensitivity and specificity for viral nucleic acids,    including HBV cccDNA, HBV DNA, HCV, HDV, HEV, and HIV, based on the CRISPR/Cas system, and promoted the development    and translation of related diagnostic kits.

4. Developed novel rapid detection methods with high sensitivity and specificity for bacterial nucleic acids,    including Carbapenem-resistant Klebsiella pneumoniae (CRKP), Brucella, Haemophilus influenzae, and Treponema    pallidum, based on the CRISPR/Cas system, and advanced the development and translation of related diagnostic kits.

Research findings have been primarily published in internationally renowned journals such as Hepatology, Cell Death    & Disease, and Emerging Microbes & Infections. We have filed 16 national patent applications for the novel methods    developed, with 4 already granted. The team has systematically elucidated the signaling network mechanisms    underlying liver failure and liver regeneration. The CRISPR-based detection methods for various pathogens possess    significant translational potential and have garnered widespread attention from peers internationally.